Burlington, Massachusetts, June 4, 2021 (Global News Service) – Flexion Therapeutics, Inc. (NASDAQ:Flex) Today announced the provision of equity incentive subsidies to 5 new employees, including 8,510 restricted stock units. The Remuneration Committee of the Board of Directors approved the grant with an effective date of June 1, 2021. According to NASDAQ Listing Rules 5635(c)(4).
The vesting period of restricted stock units is four years and 25% of the shares will be vested on each annual anniversary of the applicable vesting start date, provided that the new employee has a continuous service relationship with the company.
Restricted stock units are subject to the terms and conditions of the company’s 2013 equity incentive plan and the restricted stock unit agreement covering the grant.
About flexion therapy
Flexion therapy (NASDAQ stock code:Flex) Is a biopharmaceutical company focused on the development and commercialization of new topical therapies for patients with musculoskeletal diseases, starting with osteoarthritis, the most common form of arthritis. The company’s core values are focus, originality, tenacity, transparency and fun.Please visit flexiontherapeutics.com.
Vice President of Corporate Communications and Investor Relations
Flexion Therapy Company